GlobalData estimates that the global Chronic Myelogenous Leukemia (CML) therapeutics market was
valued at $1,089m in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 24% to reach
$3,246m in 2010. The market is forecast to grow at a CAGR of 11% over the next seven years to reach
$6,675m by 2017. This decline in growth rate is primarily attributed to the patent expiry of Gleevec in 2015 which would be offset by the expected launch of two promising pipeline molecules, Omapro (omacetaxine mepesuccinate) and bosutinib in 2014. The market remains well-served with the current market products, most of which are significantly efficacious in their respective target areas. Entry of first-in-class molecules in the market will be the primary driver for market growth. Essentially, the global CML market is heading towards a phase of continuous growth, leveraging the current opportunities.

GlobalDatas research indicates that the CML pipeline is strong, with 18 molecules in various phases of
clinical development with 13 first-in-class (FIC) molecules. Filed and Phase III have FIC molecules such
as Omapro (omacetaxine mepesuccinate) and bosutinib which possess new mechanisms of action to
treat CML. To date, both the pipeline products have shown promising clinical study results which would
warrant their use in CML. Omapro is in the filed stage, and acts as a Cyclin-D1, Mcl-1 and c-Myc proteins
synthesis inhibitor and is effective for imatinib-resistant patients with the T315I mutation. Bosutinib, a
Phase III molecule, is a dual Src and ABL inhibitor with activity against most mutants of Bcr-Abl (Breakpoint cluster region/Abelson translocation) and decreased toxicity.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Chronic-Myelocytic-Leukemia-CML-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

ChemGenex Pharmaceuticals, Pfizer Inc., Ariad Pharmaceuticals, Synta Pharmaceuticals Corp. and
Piramal Life Sciences Limited are expected to be the key players in the CML therapeutics market. The
existing market landscape remains competitive, because the treatment of CML relies on established
therapies like Gleevec, Sprycel and Tasigna. The market scenario will change after the launch of newer
disease-modifying therapies such as Cyclin-D1, Mcl-1 and c-Myc protein synthesis inhibitors, Abl and srcfamily kinase inhibitors, DNA synthesis inhibitors, Hsp90 inhibitors, dual Bcr-Abl and Lyn-kinase inhibitors, Bcr-Abl inhibitors and RAS inhibitors, Bcr-Abl kinase inhibitors, tyrosine kinase inhibitors, Bcr-Abl/JAK2 inhibitors and heat shock protein 32 (Hsp32) inhibitors with enhanced permeability and retention effect (EPR).

GlobalData, the industry analysis specialist, has released its new report, Chronic Myelogenous
Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is
an essential source of information and analysis on the global CML therapeutics market. The report
identifies the key trends shaping and driving the global CML therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CML therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Chronic-Myelocytic-Leukemia-CML-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Visit our report store: http://www.globaldata.com

For more details contact:

[email protected]
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782